# Blueprint Medicines Corporation (BPMC) Source: https://www.quantisnow.com/company/BPMC Generated: 2026-11-11T20:48:18.860Z - Ticker: BPMC - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Pharmaceutical Preparations - IPO year: 2015 - Website: blueprintmedicines.com ## About Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Blueprint Medicines Corporation has a strategic research collaboration with The University of Texas MD Anderson Cancer Center for accelerating development of BLU-222, an investigational precision therapy that targets cyclin-dependent kinase 2. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. ## Latest BPMC news and filings - 2025-07-29 00:52 UTC [SEC Form 15-12G filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-blueprint-medicines-corporation-6135097) - 2025-07-25 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-effect-filed-by-blueprint-medicines-corporation-6132360) - 2025-07-21 23:50 UTC [SEC Form 4] [Chief Financial Officer Landsittel Michael returned 51,102 shares to the company and was granted 21,353 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-landsittel-michael-returned-51102-shares-to-the-6127215) - 2025-07-21 23:50 UTC [SEC Form 4] [Director Dable Habib J returned 3,902 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-dable-habib-j-returned-3902-shares-to-the-company-6127213) - 2025-07-21 23:49 UTC [SEC Form 4] [Principal Accounting Officer Hurley Ariel was granted 2,460 shares and returned 16,146 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/principal-accounting-officer-hurley-ariel-was-granted-2460-shares-and-6127210) - 2025-07-21 23:49 UTC [SEC Form 4] [Director Tsai John returned 3,902 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-tsai-john-returned-3902-shares-to-the-company-closing-6127208) - 2025-07-21 23:49 UTC [SEC Form 4] [Director Coats Lonnel returned 6,144 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-coats-lonnel-returned-6144-shares-to-the-company-closing-6127207) - 2025-07-21 23:48 UTC [SEC Form 4] [Chief Medical Officer Hewes L. Becker was granted 21,353 shares and returned 50,165 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-hewes-l-becker-was-granted-21353-shares-6127205) - 2025-07-21 23:48 UTC [SEC Form 4] [Director Seely Lynn returned 3,902 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-seely-lynn-returned-3902-shares-to-the-company-closing-6127203) - 2025-07-21 23:47 UTC [SEC Form 4] [Chief Scientific Officer Carter Percy H. returned 56,614 shares to the company and was granted 21,353 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-carter-percy-h-returned-56614-shares-to-6127202) - 2025-07-21 23:47 UTC [SEC Form 4] [Chief Executive Officer Haviland Kate was granted 129,210 shares and returned 224,410 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-haviland-kate-was-granted-129210-shares-and-6127201) - 2025-07-21 23:47 UTC [SEC Form 4] [Chief Operating Officer Rossi Christina was granted 39,456 shares and returned 82,374 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-rossi-christina-was-granted-39456-shares-and-6127200) - 2025-07-21 23:46 UTC [SEC Form 4] [Director Borisy Alexis returned 3,902 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-borisy-alexis-returned-3902-shares-to-the-company-closing-6127199) - 2025-07-21 23:46 UTC [SEC Form 4] [Director Goldberg Mark Alan returned 3,902 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-goldberg-mark-alan-returned-3902-shares-to-the-company-6127198) - 2025-07-21 23:45 UTC [SEC Form 4] [PRESIDENT, R & D Namouni Fouad was granted 39,456 shares and returned 83,281 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-r-d-namouni-fouad-was-granted-39456-shares-and-6127197) - 2025-07-21 23:45 UTC [SEC Form 4] [Director Beckman Daniella returned 3,902 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-beckman-daniella-returned-3902-shares-to-the-company-closing-6127196) - 2025-07-21 23:45 UTC [SEC Form 4] [EVP & Chief Legal Officer Mccain Tracey L was granted 21,353 shares and returned 51,103 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-legal-officer-mccain-tracey-l-was-granted-21353-6127195) - 2025-07-21 23:44 UTC [SEC Form 4] [Chief People Officer Durso-Bumpus Debra was granted 21,353 shares and returned 51,103 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-people-officer-durso-bumpus-debra-was-granted-21353-shares-and-6127194) - 2025-07-21 23:44 UTC [SEC Form 4] [Chief Commercial Officer Lee Philina was granted 21,353 shares and returned 50,165 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-lee-philina-was-granted-21353-shares-and-6127193) - 2025-07-21 23:44 UTC [SEC Form 4] [Director Albers Jeffrey W. returned 5,777 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-albers-jeffrey-w-returned-5777-shares-to-the-company-6127192) - 2025-07-21 20:15 UTC [SEC Form SCHEDULE 13G filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-blueprint-medicines-corporation-6126840) - 2025-07-18 20:17 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125538) - 2025-07-18 20:15 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125526) - 2025-07-18 20:14 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125513) - 2025-07-18 20:12 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125496) - 2025-07-18 20:11 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125490) - 2025-07-18 20:11 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125483) - 2025-07-18 20:10 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125474) - 2025-07-18 20:09 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125469) - 2025-07-18 20:08 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125465) - 2025-07-18 20:07 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125455) - 2025-07-18 20:06 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125447) - 2025-07-18 20:05 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125414) - 2025-07-18 20:03 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125386) - 2025-07-18 20:01 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-blueprint-medicines-corporation-6125373) - 2025-07-18 19:57 UTC [SEC Form POS AM filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-blueprint-medicines-corporation-6125355) - 2025-07-18 18:58 UTC [SEC Form 25-NSE filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-blueprint-medicines-corporation-6125317) - 2025-07-18 10:09 UTC [SEC Form 8-K] [Blueprint Medicines Corporation filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant](https://www.quantisnow.com/insight/blueprint-medicines-corporation-filed-sec-form-8-k-completion-of-acquisition-6124846) - 2025-07-17 10:40 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-blueprint-medicines-corporation-6122897) - 2025-07-17 10:04 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Blueprint Medicines Corporation](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-blueprint-medicines-corporation-6122865) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BPMC - Earnings history: https://www.quantisnow.com/earnings/BPMC - Dividend history: https://www.quantisnow.com/dividends/BPMC - Insider transactions: https://www.quantisnow.com/insiders/BPMC - Options chain: https://www.quantisnow.com/options/BPMC - SEC 8-K filings only: https://www.quantisnow.com/company/BPMC/8-k - RSS and alerts for BPMC: https://www.quantisnow.com/docs/rss-feeds.md